CDKN2A and non-small cell lung carcinoma: Interestingly, a recent study also found that non-squamous non-small cell lung cancer (NSCLC) tumor patients with deletion of 9p21.3, which includes CDKN2A sequence, showed worse clinical outcomes after pembrolizumab (anti-PD-1 therapy) [49].